Work

Efeitos das terapias baseadas em incretinas na motilidade gastrointestinal de um modelo animal de Esclerose Múltipla

Year: 2018
Type: dissertation
Abstract: Multiple sclerosis (MS) is a chronic inflammatory immune-mediated disease of the central nervous system (CNS) characterized by myelin sheath degradation (demyelination), gliosis and consequent neuroaxonal degeneration and disruption of neuronal signaling. In addition to central degeneration, MS also involves dysregulation of the enteric nervous system (ENS), which leads to gastrointestinal (GI) complications, namely constipation. Since therapies currently used in MS are only effective on reducing the frequency of relapses and the most progressive forms of the disease are still practically untreatable, there is the need to find new neuroprotective and anti-inflammatory therapies that can be useful in progressive stages of MS. Incretin-based therapies, namely dipeptidyl-peptidase IV (DPP-IV) inhibitors, seem to be a good alternative not only due to its proliferative, neuroprotective and anti-inflammatory properties, mainly because of consequent increased levels of Glucagon-like peptide 1 (GLP-1) and neuropeptide Y (NPY), but also to their metabolic effects at a peripheral level that can counteract some of the GI symptoms associated to the disease. However, both GI dysfunction and DPP-IV/GLP-1/NPY pathways remain practically uncharacterized in some animal models of induced-MS, such as cuprizone (CPZ)-induced demyelination mouse model.Taking all these into account, the main aim of this study was to evaluate the effects of Sitagliptin, a DPP-IV inhibitor, in the intestinal motility of the CPZ animal model, using the ileum as the target region. For this, 10-week old C57BL/6 mice were fed with an oral solution of CPZ (0.2%) for five weeks (CPZW5), followed by CPZ withdraw, in half of them, during two more weeks (CPZW7). Two control animal groups were also analyzed in the same time points (CTRLW5 and CTRLW7). Another two animal groups of seven-week CPZ experiment were also analyzed, being administered, through a jelly vehicle, with two weeks of treatment with Sitagliptin (CPZ+Sita(T)) or seven weeks of a preventive treatment of Sitaglitpin (CPZ+Sita(P)). The demographic and biochemical profile of all animal groups, where parameters like body weight, glycemia and thymus weight were analyzed, allowed to successful characterize and confirm the animal model of induced-MS. Additionally, MBP (myelin basic protein) ileal levels allowed to confirm that CPZ intoxication also induced demyelination in the ENS. The efficacy of Sitagliptin administration were confirmed through the DPP-IV activity assay in serum samples, since this activity was reduced by approximately 80% on both animal groups treated with Sitagliptin. Functional studies performed on isolated ileum from all animal groups confirmed that CPZ intoxication alters the intestinal contractile response to electrical field stimulation in an inhibitory way, which turns this a good animal model to study GI dysfunctions associated with MS, specially constipation. Moreover, the Sitagliptin treatment reverted the inhibitory effects of CPZ intoxication, since interfered with the intestinal motility in an excitatory way. The preventive treatment, in its turn, normalized the contractile response, tending to reach control group motility. This normalization appears to involve the inhibitory effects of GLP-1, not only because the blockade of GLP-1 receptor (GLP-1R) with Exendin-3 lead to an increase on intestinal motility only on groups submitted to Sitagliptin administration, but also because GLP-1R density was significantly higher in the preventive group. Finally, functional studies performed in the presence of Y1 receptor (Y1R) antagonist, BVD-10, allowed to conclude that this receptor only contributed in an inhibitory way to intestinal motility in a disease state, due to a possible alteration on Y1R expression or NPY levels. With this study, we can conclude that CPZ animal model reflects the most frequent GI dysfunction present in MS patients and the Sitagliptin appears to be a good therapeutical option, not only because of their neuroprotective and anti-inflammatory effects, but also due to their contribution to ameliorate the GI dysregulation, improving the lifestyle of MS patients.
Language: English
Field: Medicine
Open Access status: green
Award: G491858407
OpenAlex ID: W7224046317
Cites: 97
Cited by:
Related to: 10